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INTRODUCTION
Even though esophageal cancer is a common malignancy
of elderly patients in Korea, treatment results for these patients
are not satisfactory. Patients with metastatic or recurrent eso-
phageal cancer have a particularly poor prognosis owing to
their overall medical condition. Palliative surgery to relieve
dysphagia results in high morbidity (1). Endoscopic balloon
dilation/stent insertion or intraluminal radiotherapy also help
to relieve dysphagia with less morbidity than surgery, but
the median duration of survival after these treatments is only
3-6 months, which is comparable to that of patients with
untreated advanced esophageal cancer (2, 3). For these reasons,
chemotherapy has become the primary modality for treating
metastatic or unresectable recurrent esophageal cancer, both
to relieve symptoms and to prolong life, where possible.
Combination chemotherapy with 5-fluorouracil (5-FU)
and cisplatin has been widely used in esophageal cancer, with
reported response rates of 35-40% (4). Pre-operative treatment
with this regimen was tolerated reasonably well in random-
ized trials (5, 6), but the median duration of response was
generally short, the median survival was only 6-10 months,
and efficacy was limited in metastatic disease (7). Paclitaxel,
an agent with broad antitumor activity, is one of the most
active agents against esophageal cancer, showing response
rates in the 30 to 40% when used alone (8) and of 38-48%
in combination therapy with cisplatin (9, 10). Given that
esophageal cancers respond poorly to other regimens, it is
worthwhile to examine the responses of previously treated
metastatic or recurrent esophageal cancers to paclitaxel/cis-
platin combination chemotherapy. In this study, we evalu-
ated the efficacy and tolerability of biweekly paclitaxel and
cisplatin for these patients.
MATERIALS AND METHODS
Patients
Patients with metastatic or unresectable esophageal cancer
recurring after previous treatments (chemotherapy, radiation
therapy, or surgery) were eligible to participate in this study.
The clinical stage of each cancer was evaluated using a com-
plete medical history, physical examination, complete blood
count, clinical chemistry, chest radiography, computed tomog-
raphy of the chest and upper abdomen, and gastrofiberscopy
with biopsy. A whole-body bone scan was also performed for
cases showing any symptoms suggestive of bony involvement,
including abnormalities in serum calcium or alkaline phos-
phatase levels. Clinical stages for all patients were based on
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Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with
Metastatic or Recurrent Esophageal Cancer
Although various combinations of chemotherapy regimens have been tried for patients
with esophageal cancer, their duration of survival is extremely poor. In this study,
we investigated the safety and clinical efficacy of paclitaxel and cisplatin chemother-
apy in metastatic or recurrent esophageal cancer. 32 patients enrolled in this study
and the median age was 60 yr. Of all the 32, 28 patients (88%) had been treated
previously, 22 of them with chemotherapy or radiation therapy. All patients in the
study received biweekly paclitaxel (90 mg/m
2) followed by cisplatin (50 mg/m
2). One
patient (3%) responded completely, and 12 patients (38%) showed a partial response;
in 9 patients (28%) the disease remained stable, and in 10 patients (31%) it pro-
gressed. The objective response rate was 41%. The median duration of response
was 4.8 months, and the median overall survival in all patients was 7 months. The
1-yr and 2-yr survival rates were 28.1% and 7.1%, respectively. Grade 3 or 4 of
neutropenia and anemia were observed in 6 (19%) and 5 (16%) patients, respec-
tively. The major non-hematologic toxicity was fatigue, but most of them could man-
ageable. In conclusion, biweekly paclitaxel and cisplatin is effective in patients with
metastatic or recurrent esophageal cancer. 
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the revised American Joint Committee (AJC) system. Further
eligibility requirements were as follows: voluntary informed
consent in writing; age <75 yr; Eastern Cooperative Oncology
Group (ECOG) performance status ≤2; life expectancy >12
weeks; and adequate hematological, renal, and hepatic func-
tion (WBC ≥3,000/ L, granulocytes ≥1,500/ L, platelets
≥100,000/ L, total bilirubin <1.3 mg/dL, and creatinine
clearance >60 mL/min). Exclusion criteria were: pre-existing
neurotoxicity >WHO criteria grade 1, active infection, other
serious underlying medical conditions that would impair the
ability of the patient to receive the planned treatment, or in-
adequate calorie and fluid intake.
Treatment protocol and dose modification
Paclitaxel (90 mg/m2) and cisplatin (50 mg/m2) were admin-
istrated by intravenous (i.v.) infusion every 2 weeks. Thirty
minutes prior to the paclitaxel infusion, each patient received
20 mg dexamethasone, 50 mg ranitidine, and 5 mg chlor-
pheniramine maleate i.v., to prevent hypersensitivity reac-
tions. After prehydration with at least 1 L of normal saline,
the calculated dose of paclitaxel, diluted in 500 mL of nor-
mal saline, was infused over 3 hr. The calculated dose of cis-
platin was then administered over 3 hr, followed by posthy-
dration with 3 L of normal saline over 24 hr. Ondansetron
(8 mg, i.v.) was routinely given. Patients received further
cycles of chemotherapy only when the absolute neutrophil
count was ≥1,000/ L and platelets ≥150,000/ L. The
paclitaxel dose was reduced to 75% of the original dose in
subsequent courses if one of the followings occurred: grade
3 neutropenia with infection; grade 4 neutropenia; grade 3
thrombocytopenia with bleeding that required platelet trans-
fusion; and over grade 3 sensory neurotoxicity. In cases of
fatigue or asthenia above grade 3, treatment was postponed
for 1 week and restarted when the patient had recovered to
below grade 2. After three courses of chemotherapy, progres-
sive patients were excluded. Patients showing disease regres-
sion received additional courses of chemotherapy, up to a max-
imum of eight courses.
Treatment assessment
The clinical restaging procedure included all the studies
that had shown abnormal findings prior to treatment. To evalu-
ate toxicity, a physical examination, complete blood count,
and blood chemistry were performed at the 8th to 12th day
after chemotherapy. To evaluate responses, CT scans of the
chest and abdomen, with ultrasonography and endoscopy
when appropriate, were repeated after the third and sixth cycles
and after the discontinuation of therapy. Responses were eval-
uated using WHO criteria. A complete response was defined
as the complete disappearance of all clinical evidence of dis-
ease, persisting for more than 4 weeks. A partial response was
defined as a decrease by at least 50% reduction in the sum
of the products of the largest perpendicular diameters in all
measurable lesions, including esophageal wall thickness or
at least a 30% reduction of the largest diameters in uni-dimen-
sional disease (evaluable disease) for at least 4 weeks, with no
evidence of progression or of the development of new lesions.
Progressive disease was defined as an increase in a previous
lesion by more than 25%, or the development of any new
lesion. Stable disease was defined as any change in the previous
lesion that did not fit into either the partial response or pro-
gressive disease categories. DeMeester symptom scores (11)
were used by patients to rate their swallowing symptoms on
a scale of 0-3 at the beginning of chemotherapy and the best
relief during chemotherapy. The scoring system is defined as
follows; 0=no dysphagia, 1=mild, i.e. with solids, requiring
modification of diet to soft foods, 2=moderate, i.e. difficulty
with soft foods, predominantly liquid diet, 3=severe, i.e. ob-
structed, needing medical intervention for dilatation or bolus
obstruction. Toxicities were evaluated according to the National
Cancer Institute Common Toxicity Criteria (NCI-CTC).
Statistical methods
Overall survival was measured from the date when the treat-
ment began to the date of death, or of the most recent follow-
up visit. The duration of response was measured from the
date that the response was noted to the date that progression
was confirmed, or to the last visit without progression. The
time to progression was measured from the date the treatment
began to the date of progression, or to the last visit without
progression. The statistical analysis was performed using SPSS
software (SPSS, Chicago, IL, U.S.A.). All survival data were
updated to June 2004. Median survival times and survival
curves were estimated using the method of Kaplan and Meier
and were compared using a log-rank test. A value of p=0.05
(two-sided) was considered the limit of significance.
RESULTS
Patient characteristics
Between April 1999 and June 2003, 38 eligible patients
with esophageal cancer were enrolled. Of these 38 patients,
6 patients were ineligible: 3 patients had follow-up loss after
one cycle of chemotherapy, 2 patients were dropped out because
of economic condition and one patient had double primary
tumor (esophageal and lung cancer). Therefore, 32 patients
were eligible for analysis. Patient characteristics are present-
ed in Table 1. All the patients were male and had confirmed
squamous cell carcinoma. Their median age was 60 yr (range
48-74 yr). As indicated in Table 1, 28 patients (88%) had
been treated previously. Ten patients (31%) had received nei-
ther chemotherapy nor radiotherapy; either metastatic disease
was found at diagnosis or they had relapsed after receiving620 S.-H. Cho, I.-J. Chung, S.-Y. Song, et al.
only surgery. Nineteen patients (59%) had received chemother-
apy with 5-FU and cisplatin, 18 patients (56%) had received
radiation therapy with or without concurrent chemotherapy.
Twenty patients (63%) had metastatic lesions. The predom-
inant metastatic sites were the lung, liver, bone, and lymph
nodes. All patients evaluated for this study received at least
two cycles of chemotherapy.
Chemotherapy delivery
The median number of cycles received was five, with a range
of from two to eight cycles; 151 treatment cycles were deliv-
ered in total. Of the 32 patients, 26 pateints (81%) received
more than three cycles of chemotherapy, and 13 patients (41%)
received more than six cycles. No patients had any further
treatment after this combination chemotherapy. The median
interval between cycles was 19 days (range, 13-36 days), owing
to delayed hematologic recovery and asthenia. The planned
and achieved dose intensities for cisplatin were 25 mg/m2/week
and 19.2 mg/m2/week, respectively; for paclitaxel, they were
45 mg/m2/week and 33.5 mg/m2/week, respectively.
Efficacy
Among the 32 patients, 28 patients had measurable dis-
ease and 4 patients had evaluable disease. One patient (3%)
showed a complete response (CR), 12 (38%) had partial res-
ponses (PR), 9 (28%) had stable disease (SD), and in 10 patients
(31%) the disease progressed (PD) (Table 2). The objective
response was 41%. The CR patient still had stable disease
after three cycles of chemotherapy, but reached CR after six
cycles. Seven partial responses were seen among the 10 che-
motherapy- or radiotherapy-naive patients, and 6 of 22 patients
previously treated with chemotherapy or radiotherapy respond-
ed either completely (one patient) or partially (five patients).
The objective response among naive patients was significantly
higher than among the others (p=0.049, two-sided Fisher’s
exact test). Follow-up dysphagia scores were available for 29
patients. 11 patients (34%) had an improvement of at least
one grade in dysphagia score after treatment and 12 patients
(37%) showed no change of swallowing difficulty. Only 6
patients (19%) had a progression of dysphagia. For responders,
the median duration of response was 4.5 months (range, 1.0-
49.2 months), and the median time to progression for all
patients was 5.0 months (range, 1.3-52.6 months).
Safety
The main hematologic toxicities observed were anemia
and neutropenia. Over grade 3 of neutropenia and anemia
were observed in 6 (19%) and 5 (16%) patients, respectively.
Thrombocytopenia was rare. Neutropenic infection developed
in 2 patients (6%) with pneumonia, who recovered after treat-
ment with antibiotics. Grade 1 or 2 sensory neurotoxicity was
observed in 10 patients (50%); sensory neurotoxicity over
grades 3 did not occur. The major non-hematologic toxicity
was fatigue, which spontaneously resolved after 1 or 2 weeks
of rest. One patient developed grade 3 hepatotoxicity after six
cycles of chemotherapy. Therapy was stopped, and the patient
recovered spontaneously after 2 months. There was no treat-
ment-related mortality. There were no significant differences
in hematologic or non-hematologic toxicities between chemo-
therapy- or radiotherapy-naive patients and the others (Fig. 1).
Characters Number %
Number of patients 32
Sex
Male/Female 32/0 100/0
Median age (range) (yr) 60 (48-74)
ECOG performance status
09 2 8
11 8 5 6
25 1 6
Histology
Squamous cell carcinoma 32 100
Tumor location
Upper 6 19
Middle 15 47
Lower 11 34
Disease status
Metastatic 20 61
Recurrent 28 85
Dysphagia
06 1 9
11 7 5 3
29 2 8
Previous treatment 28 85
Chemotherapy 19 59 
Radiotherapy 18 56 
Surgery 11 34 
No treatment 10 31 
Sites of metastasis
Lung 16 38
Liver 11 26
Bone 5 12
Lymph node 4 8
Others 2 5
Table 1. Patient characteristics
All patients
(n=32)
Results
Patients without 
previous
chemotherapy 
or radiotherapy
(n=10)
Patients with 
previous
chemotherapy
or radiotherapy
(n=22)
CR 1 (3%) 0 1 (4%)
PR 12 (38%) 7 (70%) 5 (23%)
CR+PR 13 (41%) 7 (70%) 6 (27%)
SD 9 (28%) 2 (20%) 7 (32%)
PD 10 (31%) 1 (10%) 9 (41%)
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Survival
The median overall survival time of all patients was 7 mon-
ths (95% CI, 5.13-8.87). The median overall survival time
of responding patients was 10 months (95% CI, 4.95-15.05;
range, 5-51 months) compared with 5 months (95% CI 3.85-
6.15, range 2-20 months) for non-responding patients. This
increased survival time was significant (p=0.0069). The 1-yr
and 2-yr survival rates of all patients were 28.1% and 7.1%,
respectively (Fig. 2).
DISCUSSION
Esophageal cancer is one of the most difficult malignancies
to manage, with early extension into adventitia or through
the esophageal wall, and regional lymph node involvement
by the time of diagnosis. Despite treatment with aggressive
surgical resection, the overall 5-yr survival rate is only 20%,
and the majority of patients relapse both locoregionally as
well as at distant sites (12, 13). To overcome this poor prog-
nosis, multimodal treatment is playing an increasingly impor-
tant role in the management of esophageal cancer. Currently
available preoperative chemoradiation therapy, followed by
surgery, achieves a complete response in 20-40% of patients,
with a 5-yr survival of 25-35% (14, 15). However, half of all
patients are unresectable or metastatic at presentation, and
65-75% relapse after surgical resection. The effect of chemo-
therapy on survival in patients with metastasis or relapsed
disease is unclear, owing to a lack of randomized phase III
trials comparing chemotherapy to best supportive care. Never-
theless, chemotherapy would be warranted if it led to pallia-
tion of symptoms and/or to prolongation of life.
Reduced tolerance to toxic chemotherapy regimens in pa-
tients with metastatic or recurrent esophageal cancer is the
result of larger tumor burdens, older ages, and comorbidities
attributable to tobacco use and alcohol consumption. Hence,
different chemotherapy regimens are needed for these patients.
Bleiberg et al. (7) reported a response rate of 35% in metastatic
esophageal cancer to combination chemotherapy with 5-flu-
orouracil and cisplatin. In spite of this response rate, this regi-
men is not the standard treatment for metastatic esophageal
cancer, owing to a high incidence of treatment-related deaths
(16%).
Recently, several new agents such as paclitaxel, irinotecan,
and vinorelbine have shown promising activity in the treat-
ment of refractory or metastatic esophageal cancer (8, 16,
17). Petrasch et al. (18) treated 24 patients with cisplatin (50
mg/m2) and paclitaxel (90 mg/m2), administered biweekly.
Patients in that study had metastatic or relapsed disease after
surgery, without previous chemotherapy. They had a response
rate of 40%, and a median of 8 months progression-free sur-
vival. Even though the response rates of Petrasch’s and our
report were similar, the progression-free survival is different
(8 months vs. 5 month, respectively). It may be originated
from the low achieved dose intensity in this study. Van der
Gaast et al. (19) used higher doses (60 mg/m2 cisplatin, 180
mg/m2 paclitaxel). Using the same high doses, Polee et al.
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Fig. 1. NCI-CTC toxicities compared treatment naive and previous treated patients.
Fig. 2. Kaplan-Meier survival curve for responding (n=13) and non-
responding patients (n=19) (p=0.0069). 
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(20) reported a 43% response rate, but 31% of patients showed
grade 3 or 4 neutropenia, and 63% had grade 1 or 2 sensory
neurotoxicity.
In this study, 28 patients (88%) had been treated previously,
22 (69%) of those with chemotherapy or radiotherapy. The
overall response rate was 41%, comparable to that seen by
Polee et al. with higher doses of paclitaxel and cisplatin. The
objective response was higher in chemoradiotherapy-naive
patients (70%) than in others (27%), and this combination
chemotherapy dose may be satisfactory for these patients.
Responders to chemotherapy also had a significant survival
benefit compared with non-responders, showing the effective-
ness of chemotherapy for metastatic or recurrent esophageal
cancer.
Although squamous cell carcinomas have become increas-
ingly less common over the past two decades and now account
for approximately 40% of all esophageal malignances report-
ed, all of our patients had confirmed squamous cell carcinoma
and this result showed the high activity of combination thera-
py for tumors of this histology (21, 22). Considering the poor
medical condition usually associated with previously treated
patients, this regimen was fairly well tolerated. Although 6
patients (19%) developed grade 3 or 4 neutropenia, serious
infections were not observed. Sensory neurotoxicity was seen
in 16 patients (50%), all with grade 1 or 2. It seems to be
associated with dose reduction as toxicity grading, and there
was no severe sensory neurotoxicity including motor weak-
ness. No significant differences were noted in hematologic
or non-hematologic toxicities between chemoradiotherapy-
naive patients and the others.
At the point of the aim of palliative therapy, the improve-
ment of dysphagia via tumor regression is important. In this
study, 11 patients (34%) showed the improvement of dys-
phagia. 12 patients (37%) had no change of dysphagia, but
5 patients of them showed no dysphagia (score 0) at the begin-
ning of treatment and maintained normal swallowing dur-
ing treatment. Remainder of them also maintained as a state
of solid intake (score 1). 
In conclusion, a biweekly schedule of paclitaxel and cis-
platin at the dose used in this study is not only effective and
well tolerated in metastatic or recurrent esophageal cancer
patients, especially in chemotherapy- or radiotherapy-naive
patients, but also effective in improvement of dysphagia.
Although moderate effects were shown in patients that had
been treated previously with chemotherapy or radiotherapy,
further study of other, perhaps higher, doses of paclitaxel or
cisplatin may be needed to improve responses in these patients.
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